Brain

Article	Citations
Reply: Is postural tachycardia syndrome a psychogenic disorder?; Notes on establishing fear conditioning as causal in the postural orthostatic tachycardia syndrome; Patients with POTS fear that data o	343
The axon initial segment as a source of neuropathic pain	332
De novo variants in ATXN7L3 lead to developmental delay, hypotonia and distinctive facial features	292
Clinical dimensions along the non-fluent variant primary progressive aphasia spectrum	281
Impaired ribosome-associated quality control of C9orf72 arginine-rich dipeptide-repeat proteins	170
Correction to: Variants in the SK2 channel gene (KCNN2) lead to dominant neurodevelopmental movement disorders	164
Proust and his neurologists: the challenge of functional disorders	164
Thalamostriatal disconnection underpins long-term seizure freedom in frontal lobe epilepsy surgery	164
Methodological drawbacks in the alleged association between foetal sonographic anomalies and autism	164
Dysregulated cortical excitability and tau phosphorylation in a β3 integrin mouse model of autism	155
Lesion correlates of impaired acoustic-phonetic perception after unilateral left hemisphere stroke	154
Clinical and genetic characterization of a progressive RBL2-associated neurodevelopmental disorder	149
Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: a pathophysiological annotation	147
Dysfunction of the magnocellular subdivision of the visual thalamus in developmental dyslexia	145
Clinical and genetic spectrum of 355 Chinese children with epilepsy: a trio-sequencing-based study	136
Associations between accelerated forgetting, amyloid deposition and brain atrophy in older adults	136
Deep brain stimulation: a tale of two targets … and closing the loop	136
Trigeminal nerve microstructure is linked with neuroinflammation and brainstem activity in migraine	133
Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1	127
Somatic variants of MAP3K3 are sufficient to cause cerebral and spinal cord cavernous malformations	126
Source-sink connectivity: a novel interictal EEG marker for seizure localization	124
Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson’s disease	124
18F-MK-6240 tau-PET in genetic frontotemporal dementia	123
The inferior fronto-occipital fasciculus: bridging phylogeny, ontogeny and functional anatomy	121
3T MRI of rapid brain activity changes driven by subcallosal cingulate deep brain stimulation	121

We’re all in this together: a rejoinder to Masud Husain’s (rant) editorial	121
The efficacy and deficiency of contemporary treatment for spinal cord arteriovenous shunts	120
Biallelic ADAM22 pathogenic variants cause progressive encephalopathy and infantile-onset refractory epilepsy	117
The use of optical coherence tomography in neurology: a review	113
Biallelic FRA10AC1 variants cause a neurodevelopmental disorder with growth retardation	109
Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline	106
‘Seeding’ the idea of early diagnostics in synucleinopathies	105
Mapping the peripheral immune landscape of Parkinson’s disease patients with single-cell sequencing	103
Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development	102
Distinct subcellular autophagy impairments in induced neurons from patients with Huntington's disease	102
Brain repair mechanisms after cell therapy for stroke	101
From bugs to brain: unravelling the GABA signalling networks in the brain–gut–microbiome axis	100
Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease	100
A data-driven study of Alzheimer's disease related amyloid and tau pathology progression	92
The vascular contribution of apolipoprotein E to Alzheimer’s disease	91
‘Hippocampal innate inflammatory gliosis only’ in pharmacoresistant temporal lobe epilepsy	88
Genetically identical twin-pair difference models support the amyloid cascade hypothesis	87
Optogenetic stimulation of the superior colliculus suppresses genetic absence seizures	87
Speech and language markers of neurodegeneration: a call for global equity	85
ActivatingRAC1variants in the switch II region cause a developmental syndrome and alter neuronal morphology	84
Gain-of-function and loss-of-function variants in GRIA3 lead to distinct neurodevelopmental phenotypes	83
Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups	83
Correction to: New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy	81
Midbrain cytotoxic T cells as a distinct neuropathological feature of progressive supranuclear palsy	79
Genome-wide association study of neuropathological features in Lewy body disease	79
Hitching a ride on exosomes: a new approach for the delivery of siRNA-mediated therapies	78
Multiple sclerosis in Denmark (1950–2023): mean age, sex distribution, incidence and prevalence	78
Synaptic dysregulation in a mouse model of GRIN2D developmental and epileptic encephalopathy	77
Reply: Unblinding in the lecanemab trial in Alzheimer’s disease	76
The interictal suppression hypothesis is the dominant differentiator of seizure onset zones in focal epilepsy	75
Defective lipid signalling caused by mutations inPIK3C2Bunderlies focal epilepsy	75
Multimodal mapping of regional brain vulnerability to focal cortical dysplasia	74
Long-term neuropsychological trajectories in children with epilepsy: does surgery halt decline?	74
Demystifying interictal discharges and seizure initiation in focal epilepsy	74
Multiple lines of evidence for disruption of nuclear lamina and nucleoporins in FUS amyotrophic lateral sclerosis	74
Periventricular remyelination failure in multiple sclerosis: a substrate for neurodegeneration	74
Evolutionary perspectives on mRNA signatures of neurodegeneration-related brain remodelling	73
Reply: From early limbic inflammation to long COVID sequelae	73
Extra-cranial cholinergic lesions in dementia with Lewy bodies	73
The three deceits of bureaucracy	73
New mechanistic insights into hereditary spastic paraplegias	72
Cytotoxic T cells and plasma cells dominate early in temporal lobe epilepsy with GAD antibodies	72
GGC repeat expansions in NOTCH2NLC cause uN2CpolyG cerebral amyloid angiopathy	72
Biallelic null variants in PNPLA8 cause microcephaly by reducing the number of basal radial glia	72
Functional network reorganization precedes apathy in Parkinson’s disease: a neural marker of risk?	70
Preclinical type 2 diabetes mellitus subtypes: new insights into diabetes, depression and dementia	70
The low dimensionality of post-stroke cognitive deficits: it’s the lesion anatomy!	70
Stuttering associated with a pathogenic variant in the chaperone protein cyclophilin 40	70
BMP receptor blockade overcomes extrinsic inhibition of remyelination and restores neurovascular homeostasis	70
Deciphering the impact of coding and non-coding SCN1A gene variants on RNA splicing	69

Disruption of DNA methylation underpins the neuroinflammation induced by targeted CNS radiotherapy	69
Cross-seeding by prion protein inactivates TDP-43	69
Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment	68
Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis	68
A sensory neuron-specific long non-coding RNA reduces neuropathic pain by rescuing KCNN1 expression	67
Clinically relevant mitochondrial-targeted therapy improves chronic outcomes after traumatic brain injury	67
How COVID-19 affects microvessels in the brain	66
Multicentre analysis of seizure outcome predicted by removal of high-frequency oscillations	66
Structural covariance analysis for neurodegenerative and neuroinflammatory brain disorders	66
Integrative miRNA–mRNA profiling of human epidermis: unique signature of SCN9A painful neuropathy	66
The potential of serum neurofilament as biomarker for multiple sclerosis	66
Clinical features and prognostic factors in adults with brain abscess	65
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings	64
Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit	64
The spectrum of disease and tau pathology of nodding syndrome in Uganda	64
Integrative genomics reveals pathogenic mediator of valproate-induced neurodevelopmental disability	63
Loss-of-function variants inMYCBP2cause neurobehavioural phenotypes and corpus callosum defects	62
Novel insight into TRPV1-induced mitochondrial dysfunction in neuropathic pain	62
The neuroethics of disorders of consciousness: a brief history of evolving ideas	61
Multifaceted nanoparticles: emerging mechanisms and therapies in neurodegenerative diseases	61
Clinical and MRI measures to identify non-acute MOG-antibody disease in adults	61
Extracellular vesicle biomarkers for complement dysfunction in schizophrenia	61
Correction to: Blood–brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound	60
Neural stem cell therapies for spinal cord injury repair: an update on recent preclinical and clinical advances	60
From shadows to spotlight: the evolution of migraine stigma since the 17th century	59
How modular are modules in visual cortex?	59
Repeat conformation heterogeneity in cerebellar ataxia, neuropathy, vestibular areflexia syndrome	59
Anatomo-functional basis of emotional and motor resonance elicited by facial expressions	58
Amyloid-β predominant Alzheimer’s disease neuropathologic change	58
Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration	58
Correction to: Expanded clinical phenotype spectrum correlates with variant function in SCN2A-related disorders	56
Corrigendum to: Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson’s disease	56
A novel eye-movement impairment in multiple sclerosis indicating widespread cortical damage	56
Multicompartmental models and diffusion abnormalities in paediatric mild traumatic brain injury	56
Sorting out Parkinson’s disease: one cell at a time	55
In silico versus functional characterization of genetic variants: lessons from muscle channelopathies	55
UNC13B and focal epilepsy	55
Untangling white matter fibre changes in Alzheimer's disease and small vessel disease	55
Reply: The correlation of behavioural deficits post-stroke: a trivial issue?	54
A journey towards the pot of gold	54
Random forest: random results or meaningful insights for patients with facioscapulohumeral muscular dystrophy?	53
Delineation of functionally essential protein regions for 242 neurodevelopmental genes	53
Reply: Lecanemab: turning point, or status quo? An ethics perspective	53
Reply: Do we need new MRI criteria for the diagnosis of radiologically isolated syndrome?	53
Pallido-putaminal connectivity predicts outcomes of deep brain stimulation for cervical dystonia	53
Neuromelanin as a nidus for neurodegeneration	53
The human subthalamic nucleus transiently inhibits active attentional processes	52
A passive and objective measure of recognition memory in Alzheimer’s disease using Fastball memory assessment	52
Effort avoidance as a core mechanism of apathy in frontotemporal dementia	52
Wheelchair use in genetically confirmed FSHD1 from a large cohort study in Chinese population	52
Correction to: Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females	51
White matter connections within the central sulcus subserving the somato-cognitive action network	50
The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson’s therapeutics	50
Startle responses in Duchenne muscular dystrophy: a novel biomarker of brain dystrophin deficiency	50
Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder	50
Large-scale rare variant burden testing in Parkinson's disease	50
Common and distinct fronto-striatal volumetric changes in heroin and cocaine use disorders	50
Failure of C9orf72 sense repeat-targeting antisense oligonucleotides: lessons learned and the path forward	50
Impaired value-based decision-making in Parkinson’s disease apathy	49
Basal forebrain integrity, cholinergic innervation and cognition in idiopathic Parkinson’s disease	49
Human lesions and animal studies link the claustrum to perception, salience, sleep and pain	49
Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease	49
Sleep and seizure risk in epilepsy: bed and wake times are more important than sleep duration	49
Neural basis of speech and grammar symptoms in non-fluent variant primary progressive aphasia spectrum	48
JC virus spread is potentiated by glial replication and demyelination-linked glial proliferation	48
Early onset hereditary neuronopathies: an update on non-5qmotor neuron diseases	48
How patients with multiple sclerosis acquire disability	48
Intracranial pressure spikes trigger spreading depolarizations	47
Recovery from aphasia in the first year after stroke	47
Genetic variability in sporadic amyotrophic lateral sclerosis	47
Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer’s disease	47
Cdc42GAP deficiency contributes to the Alzheimer’s disease phenotype	47
Age-related and amyloid-beta-independent tau deposition and its downstream effects	46
Tiam1 is part of a novel mechanism for morphine tolerance and hyperalgesia	46
Imaging chronic active lesions in multiple sclerosis: a consensus statement	46
Characterizing proteomic and transcriptomic features of missense variants in amyotrophic lateral sclerosis genes	46
Widespread white matter oedema in subacute COVID-19 patients with neurological symptoms	46
CGRP signalling in migraine: time to look downstream?	46
PTPA variants and the risk for Parkinson’s disease in diverse ancestry populations	45
Erratum to: Reply: Broca’s area: why was neurosurgery neglected for so long when seeking to re-establish the scientific truth? and Where is the speech production area? Evidence from direct cort	45

Morc2a variants cause hydroxyl radical-mediated neuropathy and are rescued by restoring GHKL ATPase	45
Is it time to rename hereditary cases of cerebral palsy?	45
Corrigendum to: Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity	45
Motor compensation in Parkinson’s disease: an empirical challenge with clinical implications	45
In vitro ictogenesis is stochastic at the single neuron level	44
Thalamic stereo-EEG in epilepsy surgery: where do we stand?	44
Correction to: Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates	44
Brain accumulation of lactosylceramide characterizes GALC deficiency in a zebrafish model of Krabbe disease	44
Amyloid-β-activated microglia can induce compound proteinopathies	44
Development of a novel tau propagation mouse model endogenously expressing 3 and 4 repeat tau isoforms	44
Bridging the gaps between JCV infection models and human disease	44
Cul-4 inhibition rescues spastin levels and reduces defects in hereditary spastic paraplegia models	44
Four dimensions of naturalistic language production in aphasia after stroke	44
Anterior optic pathway pathology in CNS demyelinating diseases	43
Alzheimer proteopathic tau seeds are biochemically a forme fruste of mature paired helical filaments	43
Diffusely abnormal white matter converts to T2 lesion volume in the absence of MRI-detectable acute inflammation	43
The visual cortex in the blind but not the auditory cortex in the deaf becomes multiple-demand regions	43
Seeding, maturation and propagation of amyloid β-peptide aggregates in Alzheimer’s disease	43
Broad activation of the Parkin pathway induces synaptic mitochondrial deficits in early tauopathy	43
Understanding brain calcification via N-terminal acetylation at the Golgi apparatus	43
Resting-state EEG reveals four subphenotypes of amyotrophic lateral sclerosis	43
Decomposing MRI phenotypic heterogeneity in epilepsy: a step towards personalized classification	43
The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson’s disease	43
Interleukin-17B is a new biomarker of human muscle regeneration in dystrophinopathies	43
Motor network gamma oscillations in chronic home recordings predict dyskinesia in Parkinson’s disease	42
Synaptic and cognitive impairment associated with L444P heterozygous glucocerebrosidase mutation	42
Shedding light on a novel circuit within primary motor cortex as a target for neuromodulation	42
Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis	41
Localizing epileptogenic tissues in epilepsy: are we losing (the) focus?	41
Smarter adaptive platform clinical trials in neurology	41
Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobe	41
Interpretable surface-based detection of focal cortical dysplasias: a Multi-centre Epilepsy Lesion Detection study	41
Right temporal degeneration and socioemotional semantics: semantic behavioural variant frontotemporal dementia	41
Imbalanced basal ganglia connectivity is associated with motor deficits and apathy in Huntington’s disease	41
Stimulation of frontal pathways disrupts hand muscle control during object manipulation	40
C-terminal TMEM106B fragments in human brain correlate with disease-associated TMEM106B haplotypes	40
Emotional bias modification weakens game-related compulsivity and reshapes frontostriatal pathways	40
The ageing central nervous system in multiple sclerosis: the imaging perspective	40
The functional role of the precuneus	40
ZSCAN10 deficiency causes a neurodevelopmental disorder with characteristic oto-facial malformations	40
Corrigendum to: Myopathic mitochondrial DNA depletion syndrome associated with biallelic variants in LIG3	39
Ockham’s razor, not a barber’s weapon but a writer’s tool	39
Poor statistical reporting in a spinal cord injury clinical trial	39
Cation leak through the ATP1A3 pump causes spasticity and intellectual disability	39
TGFβ4 alleviates the phenotype of Charcot–Marie–Tooth disease type 1A	39
Chasing MOG antibodies down … assays and lumbar punctures	39
Reply: The challenge of assessing invasive biomarkers for epilepsy surgery and To plan efficacious epilepsy surgery	39
Reply: An epigenetic basis for genetic anticipation in facioscapulohumeral muscular dystrophy type 1	39
The BS variant of C4 protects against age-related loss of white matter microstructural integrity	39
Reply: Methodological drawbacks in the alleged association between foetal sonographic anomalies and autism	39
One transgene, two myopathies: an MTM1 ‘cross gene therapy’ for BIN1 deficiency?	39
Interaction of motor behaviour, cortical oscillations and deep brain stimulation in Parkinson’s disease	38
Increase of HCN current in SOD1-associated amyotrophic lateral sclerosis	38
Of networked lesions and lesioned networks	38
Myelination potential and injury susceptibility of grey versus white matter human oligodendrocytes	38
Great science does not communicate itself: but who should and how?	38
Reply: Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size	38
Plasma biomarkers in chronic single moderate/severe traumatic brain injury	38
An extended amygdala circuit at the core of long-term post-sepsis psychiatric disorders	38
Reply: Looking beyond indirect lesion network mapping of prosopagnosia: direct measures required	38
Limitation of life sustaining therapy in disorders of consciousness: ethics and practice	37
Genome-wide contribution of common short-tandem repeats to Parkinson’s disease genetic risk	37
Mitochondrial dynamics and bioenergetics in Alzheimer’s induced pluripotent stem cell-derived neurons	37
Genome-wide epistasis analysis reveals significant epistatic signals associated with Parkinson’s disease risk	37
Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine	37
Multimodal layer modelling reveals in vivo pathology in amyotrophic lateral sclerosis	37
The Wernicke conundrum revisited: evidence from connectome-based lesion-symptom mapping	36
Clinicopathological correlates in the frontotemporal lobar degeneration–motor neuron disease spectrum	36
Noradrenergic alterations in Parkinson’s disease: a combined 11C-yohimbine PET/neuromelanin MRI study	36
Defining repetitive behaviours in frontotemporal dementia	36
Motivational and cognitive predictors of apathy after subthalamic nucleus stimulation in Parkinson’s disease	36
Mitochondrial damage is associated with an early immune response in inclusion body myositis	36
Dopamine and deep brain stimulation accelerate the neural dynamics of volitional action in Parkinson's disease	36
Role of pattern recognition receptors in chemotherapy-induced neuropathic pain	36
Dynamic reorganization of task-related network interactions in post-stroke aphasia recovery	36
Analysing an allelic series of rare missense variants of CACNA1I in a Swedish schizophrenia cohort	36
Reply: Neural substrates of the link between dual-task gait and dementia: an intermediary step in which direction?	36
Expedited epilepsy surgery prior to drug resistance in children: a frontier worth crossing?	35
Functional connectivity drives stroke recovery: shifting the paradigm from correlation to causation	35
Medial temporal lobe structural changes when Down syndrome and Alzheimer’s disease collide	35
Heterozygous PRKN mutations are common but do not increase the risk of Parkinson’s disease	35
Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseases	35
Ligand-free mitochondria-localized mutant AR-induced cytotoxicity in spinal bulbar muscular atrophy	35
Spreading depolarizations in ischaemia after subarachnoid haemorrhage, a diagnostic phase III study	35
Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy	35
Direct electrical brain stimulation of human memory: lessons learnt and future perspectives	35
Nifuroxazide rescues the deleterious effects due to CHCHD10-associated MICOS defects in disease models	35
Seronegative autoimmune encephalitis: clinical characteristics and factors associated with outcomes	35
Clinical features and prognostic factors in adults with viral meningitis	35
The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis	35
Neurophysiological consequences of synapse loss in progressive supranuclear palsy	35
Distal symmetric polyneuropathy in diabetes: a progressive disorder?	34
Blood–CSF barrier integrity in amyotrophic lateral sclerosis	34
Reply: Poor statistical reporting in a spinal cord injury clinical trial	34
Bobby Fischer and the delusions of a king of logic	34